


Our Target Diseases

Incurable diseases

Neurodegenerative Diseases



Revolutionize current symptom-relief treatments

Cancer

Metastatic cancer

Minimize undesirable side-effects of current treatments



Industrial Recognition



CONTACT

Address:

Unit 517, 5/F Biotech Centre 2,
No.11 Science Park West Avenue
Hong Kong Science Park, Shatin,
N.T., Hong Kong

Email: info@opertechnology.com

Tel: +852 2336 7900

Fax: +852 2336 7099

For more information:



Visit our Website



Like us on Facebook



Neural to Neural
Self to Self

Innovating for
Incurable Diseases



Autologous Neural Stem Cell
Harvest Technology
(US & HK Patented)

<http://opertechnology.com>

OPER Technology Limited

is dedicated to provoking revolutionary changes in the practice of PRECISION MEDICINE and REGENERATIVE MEDICINE, and bringing a new possibility in the new era of therapeutics that focuses on PERSONALIZED and PRECISION MEDICINE

Autologous Neural Stem Cell (ANSc) Harvest



Promising Cure for Neurodegenerative Diseases


WHY TRUST IN OPER ANSc HARVEST?

- Pioneering the use of ANScs for research and clinical purposes in the world
We are the FIRST and ONLY group in the world successfully extracting active adult NSCs from live subject without the sacrifice of life
- Innovative nanomaterial-based technology
- US and HK patented
- Cost-efficient
- Minimally invasive
- Low tendency in tumour formation
- No use of virus
- No genetic engineering
- Safe

Neurodegenerative Disease Population

(Including only AD, PD, HD, MS, SCI and Strokes)

US
>18.46M
Patients



China
>23.5M
Patients

World: Over 100M Patients

HUGE BUT UNMET MARKET

Cost & Investments

Around USD\$1000B per year for worldwide medical and economic cost on neurodegenerative diseases

High investment potential


Research/ Disease Areas (rounded in US\$ million)	2015	2016	2017
Neurodegenerative diseases	1662	1744	1744
Stem Cell Research	1429	1495	1495
Parkinson's disease	146	152	152
Alzheimer's disease	589	910	910
Stroke	286	300	300
Multiple Sclerosis	94	98	98

Funding used across the National Institute of Health, 10/02/2016

Versatility of ANSc Harvest


Clinical Platform

Serving ANScs Harvest as a treatment targeting neurodegenerative diseases



Research Platform

Providing ANScs for research and medical institutes and pharmaceutical companies



Higher Accuracy & Consistency